IDEXX Laboratories (IDXX) Investor Day 2024 summary

Strategic direction and growth drivers

• Focus remains on long-term organic growth in companion animal diagnostics, leveraging innovation in technology, business models, and customer engagement to address a $45B+ global market opportunity, with only ~15% currently served.

• Expansion of diagnostic modalities, software integration, and international reach are key pillars, with a resilient business model proven through macroeconomic cycles.

• Leveraging secular tailwinds such as an expanding and aging pet population, increased pet humanization, and higher care expectations to drive growth.

• Commercial execution emphasizes deep customer partnerships, education, and a team-based approach to drive adoption and utilization of new solutions.

• Significant opportunity to increase diagnostic utilization, with U.S. clinical visits including bloodwork rising by 0.5% per year since 2010.

Financial performance and guidance

• Achieved 12% average annual organic revenue growth and 22% EPS growth from 2018–2023, with a 48% return on invested capital.

• CAG Diagnostics recurring revenue now exceeds 80% of total revenue, growing faster than overall company revenue, with a 13% CAGR from 2015–2023 and international growth at 14%.

• Long-term financial targets reaffirmed: 10%+ annual organic revenue growth, 15–20% EPS gains, and 50–100 bps annual operating margin expansion, supported by disciplined capital allocation.

• Software and services recurring revenue posted a 20% CAGR from 2019–2023, driven by cloud adoption and strategic acquisitions.

• Free cash flow conversion consistently targets 80–90% of net income, with low capital investment intensity (4–5% of revenue).

Innovation and product pipeline

• Over $2.2B invested in R&D since 1998, fueling new platforms like InVue Dx and menu expansions for Catalyst One.

• Launch of IDEXX Cancer Dx panel in 2025, starting with canine lymphoma and expanding to cover over 50% of canine cancers within three years, at a price point suitable for wellness panels.

• InVue Dx, a novel cellular analyzer, launches Q4 2024, enabling rapid, slide-free cytology and future FNA testing for cancer diagnosis, automating high-volume procedures and integrating with digital platforms.

• Ongoing menu expansion for existing platforms and workflow innovations (e.g., SmartQC, AI-driven record summarization) enhance clinical utility and productivity.

• Software portfolio (ezyVet, Neo, Vello) and AI-powered tools (IDEXX DecisionIQ) drive diagnostics adoption, workflow efficiency, and pet-owner engagement.